Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty

Clinical Cardiology

Volumn 30, Issue 3, 2007, Pages 130-134

  Zhao, Jing Lin ^a   Yang, Yue Jin ^a   Zhang, Yuan Hui ^a   Pei, Wei Dong ^a   Sun, Yu Hua ^a   Chen, Ji Lin ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Myocardial infarction; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; ELECTROCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; Q WAVE; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBUS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD FLOW VELOCITY; CAPTOPRIL; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; ENALAPRIL; FEMALE; FOSINOPRIL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947285434     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20060     Document Type: Article

References (16)

1. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, et al.: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209
2. Ito H, Maruyama A, Iwakura K: Clinical implications of the 'no-reflow' phenomenon: A predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction. Circulation 1996;93:223-228
3. Podesser BK, Schirnhofer J, Bernecker OY, Kroner A, Franz M, et al.: Optimizing ischemia/reperfusion in the failing rat heart-improved myocardial protection with acute ACE inhibition. Circulation 2002;106(12 suppl 1):I277-I283
4. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, et al.: Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis 2006;17:463-469
5. Rentrop KP, Cohen M, Blanke H, Phillips RA: Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587-592
6. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, et al.: Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: Predictors of slow-flow and no-reflow phenomenon. Chest 2002;122:1322-1332
7. Piana RN, Paik GY, Moscucci M, Cohen D, Gibson CM, et al.: Incidence and treatment of no-reflow after percutaneous coronary intervention. Circulation 1994;89:2514-2518
8. Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus thrombolysis in patients with high risk myocardial infarction. J Am Coll Cardiol 2002;39:1713-1719
9. Kloner RA, Ganote CE, Jennings RB: The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508
10. Enseleit F, Hurlimann D, Luscher T: Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001;37(suppl 1):S21
11. Brown N, Douglas V: Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-1420
12. Kishi Y, Ohta S, Kasuya N, Sakita SY, Ashikaqa T, et al.: Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 2003;21:1347-1353
13. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, et al.: Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:316-332
14. Fennessy PA, Campbell JH, Mendelsohn FAO, Campbell GR: Angiotensin-converting enzyme inhibitors and atherosclerosis: Relevance of animal models to human disease. Clin Pharmacol Physiol 1996;23(suppl 1):S30-S32
15. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, et al.: Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739-1746
16. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, et al.: Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-539